Filicori M, Cognigni G E, Taraborrelli S, Spettoli D, Ciampaglia W, Tabarelli De Fatis C, Pocognoli P, Cantelli B, Boschi S
Reproductive Endocrinology Center, Department of Internal Medicine, University of Bologna, 40138 Bologna, Italy.
J Clin Endocrinol Metab. 2001 Jan;86(1):337-43. doi: 10.1210/jcem.86.1.7108.
Although the role that LH plays in folliculogenesis is still controversial, recent evidence points toward facilitatory actions of LH activity in ovulation induction. Thus, we compared the response to either highly purified FSH (75 IU FSH/ampoule; group A, 25 subjects) or human menopausal gonadotropin (75 IU FSH and 75 IU LH/ampoule; group B, 25 subjects) in normoovulatory GnRH agonist-suppressed women, candidates for intrauterine insemination. A fixed regimen of 2 daily ampoules of highly purified FSH or human menopausal gonadotropin was administered in the initial 14 days of treatment; menotropin dose adjustments were allowed thereafter. Treatment was monitored with daily blood samples for the measurement of LH, FSH, 17beta-estradiol (E(2)), progesterone, testosterone, hCG, inhibin A, and inhibin B, and transvaginal pelvic ultrasound was performed at 2-day intervals. Although preovulatory E(2) levels were similar, both the duration of treatment (16.1 +/- 0.8 vs. 12.6 +/- 0.5 days; P< 0.005) and the per cycle menotropin dose (33.6 +/- 2.4 vs. 23.6 +/- 1.1 ampoules; P < 0.005) were lower in group B. In the initial 14 treatment days the area under the curve of FSH, progesterone, testosterone, inhibin A, and inhibin B did not differ between the 2 groups, whereas LH, hCG, and E(2) areas under the curve were higher in group B. The occurrence of small follicles (<10 mm) and the inhibin B/A ratio in the late follicular phase were significantly reduced in group B. A nonsignificant trend toward a higher multiple gestation rate was present in group A (60% vs. 17%). We conclude that ovulation induction with LH activity-containing menotropins is associated with 1) shorter treatment duration, 2) lower menotropin consumption, and 3) reduced development of small ovarian follicles. These features can be exploited to develop regimens that optimize treatment outcome, lower costs, and reduce occurrence of complications such as multiple gestation and ovarian hyperstimulation.
尽管促黄体生成素(LH)在卵泡生成过程中所起的作用仍存在争议,但最近的证据表明LH活性在诱导排卵中具有促进作用。因此,我们比较了正常排卵且使用GnRH激动剂抑制的、准备接受宫内人工授精的女性,对高纯度促卵泡激素(FSH,75IU FSH/安瓿;A组,25名受试者)或人绝经期促性腺激素(75IU FSH和75IU LH/安瓿;B组,25名受试者)的反应。在治疗的最初14天,每天固定注射2安瓿高纯度FSH或人绝经期促性腺激素;此后允许调整尿促性素剂量。每天采集血样监测LH、FSH、17β-雌二醇(E₂)、孕酮、睾酮、hCG、抑制素A和抑制素B,并每隔2天进行经阴道盆腔超声检查。尽管排卵前E₂水平相似,但B组的治疗持续时间(16.1±0.8天 vs. 12.6±0.5天;P<0.005)和每个周期的尿促性素剂量(33.6±2.4安瓿 vs. 23.6±1.1安瓿;P<0.005)均较低。在最初的14个治疗日中,两组FSH、孕酮、睾酮、抑制素A和抑制素B的曲线下面积无差异,而B组的LH、hCG和E₂曲线下面积较高。B组小卵泡(<10mm)的发生率和卵泡晚期抑制素B/A比值显著降低。A组有更高多胎妊娠率的趋势,但差异无统计学意义(60% vs. 17%)。我们得出结论,使用含LH活性的尿促性素诱导排卵与以下情况相关:1)治疗持续时间更短;2)尿促性素消耗量更低;3)小卵泡发育减少。这些特点可用于制定优化治疗结果、降低成本并减少多胎妊娠和卵巢过度刺激等并发症发生的治疗方案。